Headlines about Alcobra (NASDAQ:ADHD) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alcobra earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.7822443677619 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern’s rankings:
- Alcobra Ltd. (ADHD) Given Consensus Recommendation of “Hold” by Brokerages (americanbankingnews.com)
- Arcturus Therapeutics, Synthetic Genomics Announce Pact to … – StreetInsider.com (streetinsider.com)
- Atossa Genetics Inc. (ATOS) is at $0.42 per share and Alcobra Ltd. (ADHD) is listed at $1.52 – Stocks Gallery (stocksgallery.com)
- Intraday Trade Strategies in Focus: Alcobra Ltd (NASDAQ: ADHD) – Alpha Beta Stock (alphabetastock.com)
- Arcturus Therapeutics, Synthetic Genomics Announce Pact to Develop Next-Generation Vaccines and Therapeutics (ADHD) (streetinsider.com)
Several analysts have commented on the stock. Zacks Investment Research downgraded shares of Alcobra from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Roth Capital downgraded shares of Alcobra from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $4.00 to $1.00 in a research report on Friday, September 29th. Finally, WBB Securities raised shares of Alcobra from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a research report on Monday, October 9th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $1.50.
Alcobra (NASDAQ ADHD) traded down 4.46% during mid-day trading on Wednesday, reaching $1.50. 230,090 shares of the company’s stock traded hands. The firm has a 50-day moving average price of $1.20 and a 200-day moving average price of $1.14. The stock’s market cap is $41.34 million. Alcobra has a 1-year low of $0.83 and a 1-year high of $2.58.
Alcobra (NASDAQ:ADHD) last posted its quarterly earnings results on Friday, August 11th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.02. Equities research analysts anticipate that Alcobra will post ($0.77) EPS for the current fiscal year.
Alcobra Company Profile
Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine.
What are top analysts saying about Alcobra Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alcobra Ltd. and related companies.